Yasmine Khan, MD
Endocrinology, Diabetes & Metabolism · Vernon, CTNPI 1972577518
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 439 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Abbott at 32.0% of the total. Reporting peaked in 2023 at $1,423 and has fallen 63.8% since, to $516 in 2025.
Across 439 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Novo Nordisk$1K
- Dexcom, Inc.$1K
- Lilly USA, LLC$622
- Xeris Pharmaceuticals, Inc.$218
- Medtronic$207
- plus $1K from 25 others
What the payments were for
- Food & beverage$6,586100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 104 | $2,116 |
| Novo Nordisk | 113 | $1,244 |
| Dexcom, Inc. | 91 | $1,097 |
| Lilly USA, LLC | 56 | $622 |
| Xeris Pharmaceuticals, Inc. | 13 | $218 |
| Medtronic(2 entities) | 8 | $207 |
| Insulet Corporation | 7 | $144 |
| Sanofi-aventis U.S. LLC | 6 | $120 |
| AbbVie | 5 | $106 |
| AstraZeneca(2 entities) | 4 | $96 |
| Amphastar Pharmaceuticals, Inc. | 3 | $82 |
| Tandem Diabetes Care, Inc. | 2 | $69 |
| Boehringer Ingelheim | 3 | $63 |
| Amgen | 2 | $49 |
| IBSA Pharma Inc. | 2 | $34 |
| Merck | 2 | $33 |
| Ascensia Diabetes Care US Inc. | 2 | $30 |
| Bayer | 1 | $29 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $27 |
| BETA Bionics, Inc. | 1 | $26 |
| Antares Pharma, Inc. | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $23 |
| Cequr Corporation | 1 | $20 |
| Gilead | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $16 |
| Companion Medical, Inc. | 1 | $16 |
| Nalpropion Pharmaceuticals LLC | 1 | $14 |
| Strongbridge US Inc. | 1 | $11 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$516
- FreeStyle Libre$118
How this compares
$6,615 in reported general payments places this provider in the 75th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 341 | $434,892 |
| OzempicSemaglutide | 288 | $385,183 |
| JardianceEmpagliflozin | 292 | $341,728 |
| Tresiba Flextouch U-200Insulin Degludec | 182 | $247,490 |
| JanuviaSitagliptin Phosphate | 132 | $159,634 |
| TrulicityDulaglutide | 85 | $153,849 |
| Humalog Kwikpen U-200Insulin Lispro | 65 | $116,450 |
| Tresiba Flextouch U-100Insulin Degludec | 157 | $106,003 |
| FarxigaDapagliflozin Propanediol | 90 | $82,084 |
| TradjentaLinagliptin | 88 | $77,124 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $75,698 |
| RybelsusSemaglutide | 46 | $71,725 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 89 | $70,311 |
| ProliaDenosumab | 39 | $69,195 |
| Teriparatide | 35 | $68,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi | $622 | $640,904545 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,244 | $471,969365 claims |
| Boehringer IngelheimJardiance, Tradjenta | $63 | $418,852380 claims |
| MerckJanuvia, Janumet | $33 | $190,988158 claims |
| AstraZenecaFarxiga | $96 | $82,08490 claims |
| AmgenProlia | $49 | $69,19539 claims |
| Johnson & JohnsonInvokana | $27 | $14,14817 claims |
| AbbVieSynthroid | $106 | $8,90180 claims |
| Sanofi-aventis U.S. LLCLantus | $120 | $6,84518 claims |
| IBSA Pharma Inc.Tirosint | $34 | $6,63028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Vernon
- Diana WagnerVernon$4K
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
- David DomenichiniBloomfield$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.